These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22146109)

  • 21. Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in Humans.
    Haraya K; Tachibana T
    Clin Pharmacokinet; 2021 Jan; 60(1):111-120. PubMed ID: 32779124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Quantitative Prediction Method for the Human Pharmacokinetics of Fc-Fusion Proteins.
    Yokoyama M; Suzuki E; Oitate M; Watanabe N
    Eur J Drug Metab Pharmacokinet; 2023 Sep; 48(5):541-552. PubMed ID: 37530974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
    Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of Human Pharmacokinetics Profile of Monoclonal Antibody Using hFcRn Transgenic Mouse Model.
    Nakamura G; Ozeki K; Takesue H; Tabo M; Hosoya KI
    Biol Pharm Bull; 2021; 44(3):389-395. PubMed ID: 33642546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma.
    Kamath AV; Lu D; Gupta P; Jin D; Xin Y; Brady A; Stephan JP; Li H; Tien J; Qing J; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1071-8. PubMed ID: 22203368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical and translational pharmacokinetics of a novel THIOMAB™ antibody-antibiotic conjugate against
    Deng R; Zhou C; Li D; Cai H; Sukumaran S; Carrasco-Triguero M; Saad O; Nazzal D; Lowe C; Ramanujan S; Kamath AV
    MAbs; 2019; 11(6):1162-1174. PubMed ID: 31219754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.
    Avery LB; Wang M; Kavosi MS; Joyce A; Kurz JC; Fan YY; Dowty ME; Zhang M; Zhang Y; Cheng A; Hua F; Jones HM; Neubert H; Polzer RJ; O'Hara DM
    MAbs; 2016; 8(6):1064-78. PubMed ID: 27232760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development.
    Xiang H; Bender BC; Reyes AE; Merchant M; Jumbe NL; Romero M; Davancaze T; Nijem I; Mai E; Young J; Peterson A; Damico-Beyer LA
    Clin Cancer Res; 2013 Sep; 19(18):5068-78. PubMed ID: 23894056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.
    Haraya K; Tachibana T; Nezu J
    Xenobiotica; 2017 Mar; 47(3):194-201. PubMed ID: 27151820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
    Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allometric Scaling of Therapeutic Monoclonal Antibodies Using Antigen Concentration as a Correction Factor: Application to the Human Clearance Prediction.
    Wang L; Qiang W; Cheng Z
    J Pharm Sci; 2016 Mar; 105(3):1335-40. PubMed ID: 26886347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.
    Li L; Gardner I; Dostalek M; Jamei M
    AAPS J; 2014 Sep; 16(5):1097-109. PubMed ID: 25004823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.
    Ternant D; Paintaud G
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S37-47. PubMed ID: 16187939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice?
    Xu Y; Langevin BA; Zhou H; Xu Z
    J Clin Pharmacol; 2020 Dec; 60(12):1573-1584. PubMed ID: 32578225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of hybrid approach based on empirical and physiological concept for predicting pharmacokinetics in humans--usefulness of exponent on prospective evaluation of predictability.
    Sayama H; Komura H; Kogayu M
    Drug Metab Dispos; 2013 Feb; 41(2):498-507. PubMed ID: 23209193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds.
    Fura A; Vyas V; Humphreys W; Chimalokonda A; Rodrigues D
    Biopharm Drug Dispos; 2008 Nov; 29(8):455-68. PubMed ID: 18989850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human.
    Haraya K; Tachibana T; Nezu J
    Drug Metab Pharmacokinet; 2017 Aug; 32(4):208-217. PubMed ID: 28734646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of tissue concentrations of monoclonal antibodies in mice from plasma concentrations.
    Mahmood I; Tegenge MA
    Regul Toxicol Pharmacol; 2018 Aug; 97():57-62. PubMed ID: 29894734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.
    Vugmeyster Y; Szklut P; Tchistiakova L; Abraham W; Kasaian M; Xu X
    Int Immunopharmacol; 2008 Mar; 8(3):477-83. PubMed ID: 18279802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A translational platform PBPK model for antibody disposition in the brain.
    Chang HY; Wu S; Meno-Tetang G; Shah DK
    J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.